The abstract is read at the publisher; the summary is JClub's.
In iFORCE, firmonertinib 160 mg once daily produced a median intracranial progression-free survival of 14.6 months in 23 EGFR-mutated NSCLC patients with brain metastases after EGFR-TKI resistance.
- Why it matters: Brain metastases in EGFR-mutated NSCLC are difficult to control after prior EGFR TKI therapy, leaving an unmet need for effective intracranial options.
- What they did: This prospective, single-center, single-arm study enrolled 23 patients with previously treated brain metastases or intracranial progression, then assessed iPFS and intracranial response while using digital spatial profiling on paired tumor and brain metastasis specimens.
- The result: Intracranial objective response and disease control rates were 34.8% and 91.3%, respectively, with treatment-related adverse events in 56.5% of patients; spatial profiling linked exon 19 deletion tumors to immune-enriched inflammatory programs and L858R tumors to tumor-intrinsic cell-cycle/DNA-repair and immune-evasion features.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.